Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses Peptonix microneedling, a copper peptide serum, as a potential hair loss treatment. Users compare it to finasteride and minoxidil, noting side effects and personal experiences with these treatments.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.

OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Dutasteride may affect testosterone levels, leading to high ferritin and iron levels, which can cause hair loss. High ferritin might be linked to past heavy drinking or hemochromatosis.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation discusses hair transplant options, comparing the US and Turkey, with suggestions to consider Mexico, Thailand, and other countries. It emphasizes starting treatments like finasteride, minoxidil, and microneedling before proceeding with a transplant.

The user did not respond to minoxidil and is considering using tretinoin to improve results. They also explored finasteride, microneedling, adapalene, red light therapy, and oral minoxidil as potential treatments.

Kintor Pharmaceutical's new hair loss treatment, KX-826, is entering the market. Users are eager to see its effectiveness before celebrating.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

The user had been using Minoxidil and Dutasteride with micro-needling but experienced hair loss after switching Minoxidil brands. Their doctor prescribed oral Minoxidil and Tretinoin, but the pharmacist suggested isotretinoin might be a more cost-effective alternative.

A user applied tretinoin to their scalp for hair loss and found brown particles in the cream. They are seeking information about these particles.

Hair loss without a white bulb may indicate mechanical damage, anagen effluvium, alopecia areata, or traction alopecia. Seeking a specialist is recommended, but access can be difficult in smaller areas.

Microneedling, ketoconazole, and tretinoin are discussed as hair loss treatments, with tretinoin favored for its long-term benefits and potential to turn minoxidil non-responders into responders. Microneedling is recommended for initial use, ketoconazole for dandruff, and tretinoin for continuous use due to its skin benefits.

Kintor changed their KX-826 pictures on Amazon after backlash over fake images. Users are skeptical about the product's effectiveness and trustworthiness, with some preferring finasteride instead.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

KY-19382, an indirubin derivative, is discussed for its potential to stimulate hair growth and create new hair follicles. The conversation seeks experiences with synthesizing, topically applying, or orally administering KY-19382.

Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.

The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.